EUGENE PRESTON: Open Payments
NPI 1134225550 · SAINT JOSEPH, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$435 in 23 payments from 10 companies in 2025. Trend: 2023 $866 · 2024 $666 · 2025 $435
Food & beverage: $435
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 5 | $85 |
| Astellas Pharma US Inc | 3 | $59 |
| Lilly USA, LLC | 2 | $54 |
| GlaxoSmithKline, LLC. | 3 | $48 |
| AstraZeneca Pharmaceuticals LP | 3 | $48 |
| ABBVIE INC. | 2 | $37 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $36 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $21 |
Products named: JARDIANCE, Veozah, TRELEGY ELLIPTA, VRAYLAR, Rybelsus, CAPLYTA, FARXIGA, Wegovy.
Industry payments across MI — which companies pay providers there.
